-
Uncategorized2 weeks ago
Advanced Imaging Technique Reveals Immune Cell Metabolic States in Blood Samples
Advanced Imaging Technique Reveals Immune Cell Metabolic States in Blood Samples
-
Uncategorized2 weeks agoMid-cap biotechs join Trump’s latest round of drug pricing deals
Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.
-
Uncategorized2 weeks ago
GSK to launch Phase 3 trial for mRNA-based flu vaccine amid resurgence for the modality
GSK’s vaccine—which targets two primary flu antigens—elicited higher immune responses in both younger and older adults in a mid-stage study. The Phase 3 launch, planned for...
-
Uncategorized2 weeks ago
ArsenalBio sacrifices ‘majority’ of staff in pivot to in vivo CAR T
After downsizing by 50% last year, Arsenal Biosciences is again laying off employees. This time, 99 people are getting cut as part of a strategic shift...
-
Uncategorized2 weeks ago
9 midsize drugmakers climb aboard Trump’s MFN train
Astellas Pharma, BridgeBio, BeOne Medicines and six other large biotechs join the 17 Big Pharmas that previously signed on to President Donald Trump’s Most Favored Nation...
-
Uncategorized2 weeks agoWhy G‑quadruplex biology is back and what it means for MYC‑driven cancers
Racura Oncology recently raised AU$34.3 (US$24.31) million to fund its RC220 clinical programmes in acute myeloid leukaemia (AML), epidermal growth factor receptor mutant (EGFRm) non-small cell...
-
Uncategorized2 weeks ago
Spatial Transcriptomics Tools May Link Tumor Organization to Treatment Response
Spatial transcriptomics has given cancer researchers a powerful way to see not only which genes are active in a tumor, but where that activity is taking...
-
Uncategorized2 weeks agoSingle-Use Comes of Age–What Comes Next?
Single-Use Comes of Age–What Comes Next?
-
Uncategorized2 weeks ago
Arrowhead’s new Redemplo findings in severe hypertriglyceridemia have analysts split
Safety and dosing are likely to be “key differentiators” for Arrowhead Pharmaceuticals as it looks to challenge Ionis Pharmaceuticals’ lead in the severe hypertriglyceridemia market.
-
Uncategorized2 weeks ago
Deal-hungry Lilly strikes up to $2.9B immuno play for Merida
With the acquisition of Merida Biosciences, Eli Lilly is gaining a precision degradation platform for therapies that selectively target and destroy pathologic antibodies for allergic and...
Ensuring safety and accountability in China’s biomedical translation system
Blood centers can help biopharma scale cell and gene therapies
Psychedelics at FDA, Mike Davis’ CDER and translating tRNAs — a BioCentury podcast
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
